Princeton, NJ—June 9, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting recently concluded in Washington, DC, USA. Government officials, health ministries, and global thought leaders in health economics and outcomes research (HEOR) from more than 80 countries convened in the US capital during an election year on May 21–25, 2016. International Meeting attendance was at an all-time high with 3,790 delegates attending, including government regulators and health technology assessment (HTA) bodies, leading researchers and academicians, public and private payers, patients and patient advocates, and other key stakeholders.

The ISPOR International Meeting convenes prominent HEOR experts in an unbiased global platform to meet, exchange information, and discuss the use of HEOR in health care decision making. The annual meeting helps to further ISPOR’s mission to promote health economics and outcomes research excellence to improve decision making for health globally.

Meeting highlights included a number of summits on HTA and patient-centered research, including a Health Technology Assessment Roundtable and a multi-stakeholder Patient Representatives Roundtable.

The conference featured three noteworthy plenary sessions. The first plenary, Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk?, focused on issues surrounding accelerated drug approvals. The second plenary session, Making Medical Decisions in an Irrational World, examined the impact of newer behavioral economic models on medical decision making. The third plenary, Contemporary Regulatory and Legislative Issues in Health Outcomes Research, featured speakers from the US Food and Drug Administration (FDA), the biopharmaceutical industry, patient advocacy, and a policy think tank who explored the impact of regulatory and legislative issues on HEOR. The conference also featured a number of other sessions on topical issues, including the use of real-world evidence in health care decision making, the increased interest in risk-sharing agreements in the US, the possibility of multi-criteria decision analysis (MCDA) as a new paradigm in health care decision making, the key components needed to make patients as partners in research a reality, the impact of precision medicine on outcomes research, and an exploration of patient perspectives of value assessment frameworks in oncology.

“ISPOR serves a vital role in convening key health care stakeholders to facilitate global communication and collaboration in HEOR,” stated ISPOR CEO and Executive Director, Nancy Berg. “The ISPOR International Meeting features a virtual ‘who’s who’ and offers an unbiased platform for leading health economists, scientists, researchers, academicians, health care bodies and decision makers, patients, and other key stakeholders to meet, dialogue, and share ideas.”

The meeting was co-chaired by Bradley C. Martin, PharmD, RPh, PhD, Professor and Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA and Eleanor M. Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA.

ISPOR also recognized a number of its 2016 Award Program recipients at the conference, including the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award that was presented to Pennifer Erickson, PhD, Co-Founder and Scientific Director of the On-Line Guide to Quality-of-Life Assessment (OLGA). Annual International Meeting Research Presentation Podium and Poster Awards were also presented at the Meeting.

Released presentations from the meeting are available here.


Posted in Announcements, ISPOR News & Press Tagged with: , , , , , , , , , , , , , ,